Investigator-Initiated Research (IIR) Program
Ionis Pharmaceuticals funds independent investigator-led research in cardiovascular/metabolic and pulmonary/allergy diseases aligned with its scientific priorities.
Funder: Ionis Pharmaceuticals
Due Dates: Rolling (submit at least 60 days before project start)
Funding Amounts: No fixed limit; award size and duration depend on project scope, budget, and Ionis resource availability.
Summary: Supports independent, investigator-initiated research in cardiovascular/metabolic diseases (e.g., severe hypertriglyceridemia) and pulmonary/allergy (e.g., hereditary angioedema) aligned with Ionis’ priorities.
Key Information: Proposals are unsolicited and investigator-driven; submission does not guarantee funding.
Description
The Investigator-Initiated Research (IIR) Program from Ionis Pharmaceuticals funds independent research projects conceived and conducted by external investigators and their institutions. The program aims to advance medical and scientific knowledge in Ionis’ areas of interest, specifically within cardiovascular/metabolic diseases (such as severe hypertriglyceridemia and related conditions) and pulmonary/allergy (with a focus on hereditary angioedema). Investigators retain full responsibility for research design, conduct, data interpretation, and publication. Proposals are evaluated based on scientific merit, alignment with Ionis’ research priorities, and resource availability.
